Selected research
Industry Research
Vandetanib API Industry Research Report 2026
Market perspective
The global Vandetanib API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vandetanib API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vandetanib API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vandetanib API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vandetanib API include Biotechnica Pharma, Epoch-Labs, Astra Zeneca, Biocar Bio-Pharm, Dibo Chemical, Junxian Biotechnology, Luoxin Pharmaceuticals, Chico Pharmaceutical and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vandetanib API market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vandetanib API Market by Company
Biotechnica Pharma
Epoch-Labs
Astra Zeneca
Biocar Bio-Pharm
Dibo Chemical
Junxian Biotechnology
Luoxin Pharmaceuticals
Chico Pharmaceutical
Sanofi
Widely Chemical
Weishi Chemical
Vandetanib API Segment by Type
Purity Greater Than 0.99
Purity Greater Than 0.995
Vandetanib API Segment by Application
Hospital
Clinic
Vandetanib API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vandetanib API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vandetanib API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vandetanib API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vandetanib API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vandetanib API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vandetanib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity Greater Than 0.99
- Purity Greater Than 0.995
Applications
- Hospital
- Clinic
Companies covered
- Biotechnica Pharma
- Epoch-Labs
- Astra Zeneca
- Biocar Bio-Pharm
- Dibo Chemical
- Junxian Biotechnology
- Luoxin Pharmaceuticals
- Chico Pharmaceutical
- Sanofi
- Widely Chemical
- Weishi Chemical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vandetanib API Market Size (2021-2032)
- 2.2.2 Global Vandetanib API Sales (2021-2032)
- 2.2.3 Global Vandetanib API Market Average Price (2021-2032)
- 2.3 Vandetanib API by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Purity Greater Than 0.99
- 2.3.3 Purity Greater Than 0.995
- 2.4 Vandetanib API by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vandetanib API Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vandetanib API Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Vandetanib API Revenue of Manufacturers (2021-2026)
- 3.4 Global Vandetanib API Average Price by Manufacturers (2021-2026)
- 3.5 Global Vandetanib API Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vandetanib API, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vandetanib API, Product Type & Application
- 3.8 Global Manufacturers of Vandetanib API, Established Date
- 3.9 Global Vandetanib API Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biotechnica Pharma
- 4.1.1 Biotechnica Pharma Company Information
- 4.1.2 Biotechnica Pharma Business Overview
- 4.1.3 Biotechnica Pharma Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biotechnica Pharma Vandetanib API Product Portfolio
- 4.1.5 Biotechnica Pharma Recent Developments
- 4.2 Epoch-Labs
- 4.2.1 Epoch-Labs Company Information
- 4.2.2 Epoch-Labs Business Overview
- 4.2.3 Epoch-Labs Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Epoch-Labs Vandetanib API Product Portfolio
- 4.2.5 Epoch-Labs Recent Developments
- 4.3 Astra Zeneca
- 4.3.1 Astra Zeneca Company Information
- 4.3.2 Astra Zeneca Business Overview
- 4.3.3 Astra Zeneca Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Astra Zeneca Vandetanib API Product Portfolio
- 4.3.5 Astra Zeneca Recent Developments
- 4.4 Biocar Bio-Pharm
- 4.4.1 Biocar Bio-Pharm Company Information
- 4.4.2 Biocar Bio-Pharm Business Overview
- 4.4.3 Biocar Bio-Pharm Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Biocar Bio-Pharm Vandetanib API Product Portfolio
- 4.4.5 Biocar Bio-Pharm Recent Developments
- 4.5 Dibo Chemical
- 4.5.1 Dibo Chemical Company Information
- 4.5.2 Dibo Chemical Business Overview
- 4.5.3 Dibo Chemical Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dibo Chemical Vandetanib API Product Portfolio
- 4.5.5 Dibo Chemical Recent Developments
- 4.6 Junxian Biotechnology
- 4.6.1 Junxian Biotechnology Company Information
- 4.6.2 Junxian Biotechnology Business Overview
- 4.6.3 Junxian Biotechnology Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Junxian Biotechnology Vandetanib API Product Portfolio
- 4.6.5 Junxian Biotechnology Recent Developments
- 4.7 Luoxin Pharmaceuticals
- 4.7.1 Luoxin Pharmaceuticals Company Information
- 4.7.2 Luoxin Pharmaceuticals Business Overview
- 4.7.3 Luoxin Pharmaceuticals Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Luoxin Pharmaceuticals Vandetanib API Product Portfolio
- 4.7.5 Luoxin Pharmaceuticals Recent Developments
- 4.8 Chico Pharmaceutical
- 4.8.1 Chico Pharmaceutical Company Information
- 4.8.2 Chico Pharmaceutical Business Overview
- 4.8.3 Chico Pharmaceutical Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chico Pharmaceutical Vandetanib API Product Portfolio
- 4.8.5 Chico Pharmaceutical Recent Developments
- 4.9 Sanofi
- 4.9.1 Sanofi Company Information
- 4.9.2 Sanofi Business Overview
- 4.9.3 Sanofi Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Sanofi Vandetanib API Product Portfolio
- 4.9.5 Sanofi Recent Developments
- 4.10 Widely Chemical
- 4.10.1 Widely Chemical Company Information
- 4.10.2 Widely Chemical Business Overview
- 4.10.3 Widely Chemical Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Widely Chemical Vandetanib API Product Portfolio
- 4.10.5 Widely Chemical Recent Developments
- 4.11 Weishi Chemical
- 4.11.1 Weishi Chemical Company Information
- 4.11.2 Weishi Chemical Business Overview
- 4.11.3 Weishi Chemical Vandetanib API Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Weishi Chemical Vandetanib API Product Portfolio
- 4.11.5 Weishi Chemical Recent Developments
5 Global Vandetanib API Market Scenario by Region
- 5.1 Global Vandetanib API Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vandetanib API Sales by Region: 2021-2032
- 5.2.1 Global Vandetanib API Sales by Region: 2021-2026
- 5.2.2 Global Vandetanib API Sales by Region: 2027-2032
- 5.3 Global Vandetanib API Revenue by Region: 2021-2032
- 5.3.1 Global Vandetanib API Revenue by Region: 2021-2026
- 5.3.2 Global Vandetanib API Revenue by Region: 2027-2032
- 5.4 North America Vandetanib API Market Facts & Figures by Country
- 5.4.1 North America Vandetanib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vandetanib API Sales by Country (2021-2032)
- 5.4.3 North America Vandetanib API Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Vandetanib API Market Facts & Figures by Country
- 5.5.1 Europe Vandetanib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vandetanib API Sales by Country (2021-2032)
- 5.5.3 Europe Vandetanib API Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Vandetanib API Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vandetanib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vandetanib API Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vandetanib API Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vandetanib API Market Facts & Figures by Country
- 5.7.1 South America Vandetanib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vandetanib API Sales by Country (2021-2032)
- 5.7.3 South America Vandetanib API Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Vandetanib API Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vandetanib API Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vandetanib API Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vandetanib API Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Vandetanib API Sales by Type (2021-2032)
- 6.1.1 Global Vandetanib API Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Vandetanib API Sales Market Share by Type (2021-2032)
- 6.2 Global Vandetanib API Revenue by Type (2021-2032)
- 6.2.1 Global Vandetanib API Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vandetanib API Revenue Market Share by Type (2021-2032)
- 6.3 Global Vandetanib API Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vandetanib API Sales by Application (2021-2032)
- 7.1.1 Global Vandetanib API Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Vandetanib API Sales Market Share by Application (2021-2032)
- 7.2 Global Vandetanib API Revenue by Application (2021-2032)
- 7.2.1 Global Vandetanib API Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vandetanib API Revenue Market Share by Application (2021-2032)
- 7.3 Global Vandetanib API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vandetanib API Value Chain Analysis
- 8.1.1 Vandetanib API Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vandetanib API Production Mode & Process
- 8.2 Vandetanib API Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vandetanib API Distributors
- 8.2.3 Vandetanib API Customers
9 Global Vandetanib API Analyzing Market Dynamics
- 9.1 Vandetanib API Industry Trends
- 9.2 Vandetanib API Industry Drivers
- 9.3 Vandetanib API Industry Opportunities and Challenges
- 9.4 Vandetanib API Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst